New distribution agreement could lead to a swift recovery

Renalytix (LSE:RENX) is at 5.35p with a £26m market cap and reports unaudited results for the 12 months to June 2026 following a change in FY to December, with no revenue growth but strong progress since the period end. This precision medicine diagnostics company raised $14m at 6p, converting the remaining $3.6m of debt. The Company’s product kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease. Revenue remains unchanged at $3m, driven by commercial test sales and sensitive to insurance reimb...